Ritter Pharmaceuticals develops novel therapeutics that modulate the gut microbiome for the treatment of gastrointestinal diseases.
Mr. Proehl has previous experience as the president and CEO of Santarus. During his time there, he oversaw the development and commercialization of the GI products UCERIS and Zegerid.
More articles on gastroenterology:
2014 pay: 5 insights into gastroenterologist compensation
How physician report cards improve colonoscopy quality: 4 things to know
Olympus alerted European hospitals of scope infection risk 2 years ago
